References
- Gronberg H. Prostate cancer epidemiology. Lancet 2003; 361: 859–64
- Murphy M, Johnston C, Whelan P, Rider L, Lloyd SN. Changing trends in prostatic cancer. BJU Int 1999; 83: 786–91
- Tannock I. Eradication of a disease: how we cured symptomless prostate cancer. Lancet 2002; 359: 1341–42
- Quinn M, Babb P, Brock A, Jones J. Cancer trends in England and Wales 1950–1999. The Stationery Office, London 2001
- Horwich A, Waxman J, Abel P, Laniado M, Dearnaley D. Tumours of the prostate. The Oxford textbook of oncology, 2nd ed, R Souhami, et al. Oxford University Press, OxfordUK 2001; 1939–71
- Ornstein DK, Rao GS, Smith DS, Andriole GL. The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate. J Urol 1997; 157: 880–3
- Shibata A, Ma J, Whittemore A. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst 1998; 90: 1230–1
- Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 289–94
- Potosky AL, Feuer EJ, Levin DL. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev 2001; 23: 181–6
- Walsh PC. Surgery and the reduction of mortality from prostate cancer. N Engl J Med 2002; 347: 839–40
- Stattin P, Johansson R, Damber J-E, Hellstrom M, Hugosson J, Lundgren R, et al. Non-systematic screening for prostate cancer in Sweden. Scand J Urol Nephrol 2003; 37: 461–5
- Gjengsto P, Eide J, Frugard A, Bakke A, Hoisaeter PA. The potentially curable prostate cancer patient and the pathways leading to diagnosis and treatment. Scand J Urol Nephrol 2004; 38: 15–8
- Selley S, Donovan J, Faulkner A, Coast J, Gillatt D. Diagnosis, management and screening of early localised prostate cancer. Health Technol Assess 1997; 1: 1–96
- NHS Centre for Reviews and Dissemination. Screening for prostate cancer. Effectiveness Matters 1997;2:1–4.
- Chamberlain J, Melia J, Moss S, Brown J. The diagnosis, management, treatment and costs of prostate cancer in England and Wales. Health Technol Assess 1997; 1: 1–53
- Farmer A. 10-minute consultation: prostatic symptoms. Br Med J 2001; 322: 1468
- Etzioni R, Cha R, Feuer EJ, Davidov O. Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol 1998; 148: 775–85
- Chokkalingam AP, Nyren O, Johansson JE, Gridley G, McLaughlin JK, Adami HO, et al. Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden. Cancer 2003; 98: 1727–34
- Wilkinson S, Chodak G. Informed consent for prostate-specific antigen screening. Urology 2003; 61: 2–4